Previous 10 | Next 10 |
‒ Plan expected to reduce costs by approximately $50 million annually ‒ ‒ Reduces Full Year 2019 Adjusted EBITDA Guidance ‒ Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced a comprehensive restructuring plan designed to reduce its cost base, furthe...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on ...
Early July is typically one of the two times each calendar year that U.S. drugmakers hike prices. Yesterday, on cue, many appeared to do just that . More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., ProShares Ultra Nasdaq Biotechnology ETF, Healthcare stocks news, Stocks on...
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit. Additional information about each case can be found at the link provided...
Welcome to Wall Street Brunch, our preview of stock market events for investors to watch during the upcoming week. You can also catch this article a day early by subscribing to the Stocks to Watch account for Saturday morning delivery. Podcast listener? Subscribe now to receive Wall ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...